top | item 28220574

Antidepressant fluvoxamine can save Covid-19 patients, McMaster research shows

37 points| ageitgey | 4 years ago |brighterworld.mcmaster.ca | reply

38 comments

order
[+] worldvoyageur|4 years ago|reply
Patrick Collison, one of the funders of this research via the Fast Grants program (https://fastgrants.org/), tweeted an excellent summary the results a few days ago:

https://twitter.com/patrickc/status/1427367934880469010

n=1,472 patients; ~1/3 reduction in hospitalization; now pursuing a larger scale trial to replicate the results

The actual research results are here:

https://www.frontiersin.org/articles/10.3389/fphar.2021.6526...

From the paper, dosage in the trial was:

" Participants received 50 mg FLV QD on day 1, then for 2 days 100 mg FLV BID, and then 100 mg FLV TID as tolerated through day 15 and then stopped. "

Fluvoxamine has been long off patent. Based on my slap-dash googling of online pharmacies, this treatment would cost under US$10 total.

The hypothesized mechanisms of action are the anti-inflammatory, anti-platelet, and potentially antiviral activities which are side effects of Fluvoxamine's psychoactive properties. These mechanisms would counter some of the more serious body responses to the more severe cases of covid.

[+] chriscappuccio|4 years ago|reply
All sigma 1 agonists in test for covid seem to work very well to prevent serious disease symptoms and death. They appear to modulate the immune system's response to the virus (including cytokine storm) which is what causes most of the damage.
[+] thesausageking|4 years ago|reply
This came out of the Together Trial project which has been looking at hundreds of existing drugs to see if any will work for COVID19:

https://www.togethertrial.com/

I'm going to be skeptical until the paper comes out. There was a lot of initial data on Hydroxychloroquine that looked good and it ended up being only noise (and bad study designs).

[+] Zelphyr|4 years ago|reply
Having taken SSRI's before, and experienced their withdrawal symptoms, I'd almost rather have COVID.
[+] bserge|4 years ago|reply
You need to taper off. And I mean really gradually over weeks. Sadly, they don't even work for me, yet doctors are hellbent on me trying them and won't prescribe anything else. Guess I'll die lol
[+] Mo3|4 years ago|reply
Taking an SSRI and it saved my life. I‘d rather be the happy motivated SSRI addict than be left with permanent lung damage etc
[+] aaaaaaaaaaab|4 years ago|reply
Brain zaps? Still better than benzo withdrawal though!
[+] tsomctl|4 years ago|reply
Having experienced both, I'd prefer to have COVID. The only reason why I'd take SSRI's for COVID is to prevent the multi month recovery of symptoms.
[+] httpsterio|4 years ago|reply
I had 0 issues when I've stopped, I've been on Voxra (bupropion) and Escitalopram. Meds that cause brain zaps like Voxra need to be stopped over a longer period of time, for me I got off them in a month after being on the max dose but for many that's way too fast as well.
[+] sergiomattei|4 years ago|reply
Currently on a selective norepinephrine reuptake inhibitor, side effects are wonky...
[+] nradov|4 years ago|reply
If fluvoxamine is used for COVID-19 treatment it will probably only be administered for a couple weeks so withdrawal symptoms should be minimal.
[+] miej|4 years ago|reply
why was this article posted prior to the publication of their actual research paper?
[+] raphlinus|4 years ago|reply
Because "science by PR" is the new fashion. Back in my day, we waited for the peer reviewed publication, and tied onions to our belts, which was the style at the time.
[+] fourtrees|4 years ago|reply
I'd really like to see what effect Opipramol/Insidon has on COVID patients. If the results were similar to Fluvoxamine, that would very strongly suggest that the mechanism of action is via the σ1 receptor.
[+] criticaltinker|4 years ago|reply
> “Fluvoxamine is the only treatment that, if administered early, can prevent COVID-19 from becoming a life-threatening illness,”

Actually many front-line doctors have been using a multidrug treatment based on existing medicines to successfully reduce hospitalization and death since very early on in the pandemic. One key aspect is treating patients early in the symptomatic phase with a combination of antiviral, corticosteroid, and antithrombotic medications. [1][2][3][4][5][6][7][8][9][10]

Many clinical trials have evaluated the suggested drugs in a single-drug treatment regime, but very few clinical trials have evaluated a multidrug treatment approach specifically focused on patients who are early in the symptomatic phase.

[1] Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection https://www.amjmed.com/article/S0002-9343(20)30673-2/fulltex...

[2] Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19) https://scholarlycommons.henryford.com/cgi/viewcontent.cgi?a...

[3] Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection https://rcm.imrpress.com/EN/article/downloadArticleFile.do?a...

[4] Early multidrug treatment of SARS-CoV-2 infection (COVID-19) and reduced mortality among nursing home (or outpatient/ambulatory) residents https://www.sciencedirect.com/science/article/abs/pii/S03069...

[5] Multidrug treatment for COVID-19 https://www.jstage.jst.go.jp/article/ddt/advpub/0/advpub_202...

[6] A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237953/

[7] Clofazimine broadly inhibits coronaviruses including SARS-CoV-2 https://www.nature.com/articles/s41586-021-03431-4

[8] In Silico Exploration of the Molecular Mechanism of Clinically Oriented Drugs for Possibly Inhibiting SARS-CoV-2’s Main Protease https://pubs.acs.org/doi/pdf/10.1021/acs.jpclett.0c00994

[9] Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2 https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.0c00521

[10] Repurposed Drugs, Molecular Vaccines, Immune‐Modulators, and Nanotherapeutics to Treat and Prevent COVID‐19 Associated with SARS‐CoV‐2, a Deadly Nanovector https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645867/

[+] nextaccountic|4 years ago|reply
Brazil has become a big open air experiment on the efficacy of Hydroxychloroquine, Azithromycin and/or Ivermectin, separately and together. Those specific drugs don't seem to help that much, if at all. On the other hand, they may have severe side effects. (Dexamethasone do work in critically ill patients though)

It's a tough call. I really want to support science and probably some combination of drugs in the above studies work. It's just hard to know which ones.

Related: https://www.thelancet.com/journals/lancet/article/PIIS0140-6...

[+] amanaplanacanal|4 years ago|reply
I would assume that most patients don’t seek medical care until they are having symptoms they can’t manage at home.

I don’t know how useful drugs are that have to be used in the early symptom phase. Does this require everybody to present themselves to a doctor every time they get upper respiratory symptoms?

[+] zanethomas|4 years ago|reply
It is criminal the way YouTube et al suppressed propagation of those facts.
[+] captainredbeard|4 years ago|reply
Will this be a required prophylactic soon?
[+] aaaaaaaaaaab|4 years ago|reply
Yes. You will be force-fed antidepressants. /s
[+] nradov|4 years ago|reply
Doubtful due to side effects. At most this will be a treatment for patients with confirmed infection. And then probably only after the results are reproduced in a larger clinical trial.
[+] kgin|4 years ago|reply
Can you explain more why you think this is a possibility?
[+] Tarucho|4 years ago|reply
Yes, time to invest on Viagra-making companies.
[+] machiaweliczny|4 years ago|reply
Was anyone testing "vitamine B15" effect? It seems to improve oxygen utilisation so maybe could be helpful. I can't find many articles related to covid.